Panacea Biotec FY26: A Vaccine Maker with Lipstick on a Pig

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Panacea Biotec closed FY26 with ₹640 Cr consolidated revenue—a 14% yoY bump—but booked a ₹7.4 Cr loss before tax and a ₹5.4 Cr net loss, both worsening from FY25’s ₹7.9 Cr and ₹8.4 Cr losses.

The balance sheet holds ₹64 Cr in cash and near-cash but ₹24 Cr in debt, netting to ₹40 Cr. Operating margins turned negative at −0.7%, and the vaccine segment (about 56% of revenue) bled ₹2.7 Cr in pretax losses.

DengiAll—a single-shot dengue vaccine—completed Phase III trials and awaits regulatory clearance for 2027 launch. The company hauled in new long-term vaccine orders and dodged a ₹9.16 Cr income tax demand (ITAT allowed an appeal in April 2026).

A maker that ships vaccines globally but can’t ship profits domestically.

2. Introduction

Panacea Biotec was incorporated in 1984 and sits in the bio-pharma space—vaccines, formulations, nutraceuticals, and nutrition products. It’s one of India’s larger vaccine makers and supplies WHO-prequalified polio vaccines to 50+ countries.

The company pivoted hard in March 2022 after selling its domestic pharma brand portfolio (a one-time ₹3,599 Cr windfall via exceptional income that year). That cash helped fund R&D, especially the DengiAll programme, and repay debt. By FY26, the boost had worn off. Exceptional income fell to ₹1,950 Cr for the group (still offsetting operational losses), but the core business still hasn’t turned profitable.

A promoter-heavy cap table (72.5% in Dr. Rajesh Jain and family) means aligned skin-in-the-game. An independent director resigned in March 2026; a replacement was appointed for July 2026.

The company operates through Panacea Biotec Pharma Limited (formulations, exports to 36 countries) and overseas subsidiaries. Consolidated figures include these entities.

3. Business Model: WTF Do They Even Do?

Split into two engines: vaccines and pharmaceutical formulations.

Vaccines ($56% of FY26 revenue, ₹410 Cr). DPT, polio, pentavalent (EasyFive), and hexavalent (EasySix) are core. Exports drive 46% of vaccine sales; domestic is 10%. Institutional buyers (government CMSS, GAVI, WHO-eligible facilities) are the bulk. A ₹20.79 Cr CMSS tender for Td vaccine arrived in April 2026, supply starting Sep/Oct 2026 through Nov 2028—multi-year runway. New capacity coming online for vaccine drug substance manufacturing; one facility in Baddi, Himachal Pradesh.

Formulations (44% of revenue, ₹280 Cr). Subsidiary PBPL exports generic pharmaceuticals (pain, diabetes, cardiovascular, oncology, renal, GI) to 36 countries—US, Germany, Russia, Turkey, Canada, Vietnam, Philippines, etc. Domestic share is 14%. The nano-particle Paclitaxel generic started supply to Canada in FY23.

The vaccine engine is the marquee—global prestige, regulatory moats—but it’s capital-intensive, slow to scale, and losing money hand over fist. Formulations are smaller, less flashy, and treading water on margin. Neither is a moneymaker yet.

A dual-engine model where both engines are sputtering.

4. Financials Overview

Figures are consolidated, in ₹ crore.

Revenue grew 14% yoY. EBITDA stayed flat near ₹26 Cr (4% margin). Operating losses persisted because depreciation (₹33 Cr) and interest (₹6 Cr) ate profit. The vaccine segment alone posted ₹2.7 Cr losses in FY26; formulations trotted out ₹2 Cr profit—the only thing keeping the group from free-falling.

PAT flipped from ₹8.4 Cr losses to ₹5.4 Cr losses. Exceptional income (settlement with Apotex, ₹857 Cr; deferred pharma-brand consideration, ₹1,092 Cr) masked the rot. Strip those out, and operating losses are ₹2.7 Cr.

EPS dropped to −₹0.88 (full year) from −₹1.37. No dividend—the company passed for FY26.

Quarterly Q4 (Jan–Mar 2026): Revenue ₹166.75 Cr, up 25.8% yoY. Operating profit ₹2.57 Cr. Net profit ₹0.52 Cr—the first black quarter in years. One quarter of respite after six years of red tape. Don’t party yet.

Key Moves:

April 2026: ITAT allowed appeal on ₹9.16 Cr tax demand for AY2020-21. The company dodged a bullet.

February 2026: GMP certificate revoked at the Baddi facility (EU inspectors) after a January inspection. Impact is “non-vital” EU supplies; EU revenue is 0.32%, so shrug.

March 2026: GST demand ₹22.88 Cr (₹11.44 Cr tax + ₹11.44 Cr penalty) for Apr 2019–Mar 2022. Company says it’ll appeal.

May 2026: DengiAll Phase III enrollment completed; launch expected 2027.

June 2026: DENSTAR project (DengiAll licensure in Africa, EU-funded, €11.09 Cr, 48 months).

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.